A rapid, sensitive and accurate capillary gas chromatographic assay with (63)Ni electron capture detection was developed for the determination of anastrozole in human plasma. It comprises a one-step liquid-liquid extraction procedure and gas chromatography on a capillary column using constant oven temperature. This method has been applied to the oral pharmacokinetic study of anastrozole in healthy Chinese male volunteers. Pharmacokinetic parameters of two anastrozole preparations were evaluated after single, oral administrations to 18 subjects at a dose of 1 mg in a single-blind cross-over trial. Plasma anastrozole concentration-time profiles were best described by a two-compartment model. After oral administrations of imported and domestic anastrozole tablets, the t(max) and C(max) were 1.52 +/- 1.04 h and 8.75 +/- 3.03 ng/mL for the former, and 1.43 +/- 1.12 h and 9.44 +/- 3.59 ng/mL for the latter; the elimination half-life was 46.0 +/- 25.2 h vs 41.2 +/- 8.8 h, and the area under the curve (AUC) was 423 +/- 114 ng h/mL vs 444 +/- 157 ng h/mL. The result indicates that the two products are bioequivalent.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bmc.172 | DOI Listing |
Int J Gynecol Cancer
January 2025
Memorial Sloan Kettering Cancer Center, Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA; Weill Cornell Medical College, Department of Medicine, New York, NY, USA. Electronic address:
Objective: We sought to determine the safety and efficacy of the oral progesterone antagonist onapristone in combination with anastrozole in patients with recurrent progesterone receptor-positive adult-type granulosa cell tumor of the ovary.
Methods: This was a single-institution phase II study of patients with progesterone receptor-positive adult-type granulosa cell tumor who received at least 1 prior line of chemotherapy. Patients were enrolled from November 2021 to August 2022 and tissue was evaluated for progesterone receptor status via immunohistochemistry.
Sci Rep
January 2025
Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, Fujian, China.
Macular degeneration is a leading cause of irreversible vision loss, significantly impacting quality of life. To enhance clinical practice and reduce the risk of drug-related macular degeneration, we analyzed drug-related trends using real-world data. Disproportionality analysis of adverse event reports from the FDA Adverse Event Reporting System (FAERS, 2004-2023) identified 67,683 cases involving 1402 drugs.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
AstraZeneca, Gaithersburg, MD.
The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Herein, the prespecified final overall survival (OS) analysis is reported. After the primary PFS analysis, data were collected on survival, serious adverse events, and health-related quality of life.
View Article and Find Full Text PDFJ Drug Target
January 2025
Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore, India.
Breast cancer (BC) is a substantial reason for cancer-related mortality among women across the globe. Anastrozole (ANS) is an effective orally administered hormonal therapy for oestrogen-positive (ER+) BC treatment. However, several side effects and pharmacokinetic limitations restricted the uses of ANS in BC therapy.
View Article and Find Full Text PDFCancer Med
January 2025
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, Georgia, USA.
Introduction: Emerging evidence suggests potential cardiovascular toxicities from oral endocrine therapies (ETs); however, results are conflicting. This study comprehensively examined adverse reactions of ETs and investigated cardiovascular and metabolic safety signals within the FDA Adverse Event Reporting System (FAERS).
Methods: Reports in the FAERS through December 2023 were analyzed for documented reactions to tamoxifen, letrozole, anastrozole, and exemestane in female breast cancer patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!